X

Trial Profile

Randomised, open label study of rituximab/ibrutinib vs rituximab/chemotherapy in older patients with untreated mantle cell lymphoma

Status: Active, no longer recruiting

Phase of Trial: Phase II/III

Latest Information Update: 14 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ibrutinib (Primary) ; Bendamustine; Cyclophosphamide; Doxorubicin; Prednisolone; Rituximab; Rituximab; Vincristine
Indications Mantle-cell lymphoma
Focus Therapeutic Use
Acronyms ENRICH

Most Recent Events

23 Jul 2024 Planned End Date changed from 1 Dec 2022 to 31 Dec 2026.
23 Jul 2024 Status changed from completed to active, no longer recruiting.
12 Dec 2023 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com